Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.[1][2][3]It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5]
^ abBanihashemi SR, Es-Haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, et al. (2022). "Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models". Frontiers in Immunology. 13: 836745. doi:10.3389/fimmu.2022.836745. PMC9179012. PMID 35693788.
^ abc"Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
^ abc"Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
^ ab"COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
^ ab"IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
^"۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد" [5 million doses of Razi vaccine were delivered to the Ministry of Health]. ایسنا(ISNA) (in Persian). 25 November 2021. Retrieved 27 November 2021.
razi, pars, persian, رازی, کوو, پارس, covid, vaccine, developed, iranian, razi, vaccine, serum, research, institute, covid, vaccine, based, recombinant, protein, which, being, produced, razi, vaccine, serum, research, institute, iran, this, vaccine, first, inj. Razi Cov Pars Persian رازی کوو پارس is a COVID 19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid 19 vaccine based on recombinant protein which is being produced by Razi Vaccine and Serum Research Institute Iran This vaccine is the first injectable intranasal recombinant protein corona vaccine 1 2 3 It s the second Iranian COVID 19 vaccine reaching human trials 1 and is currently in phase III of clinical research during which it s compared to the Sinopharm BIBP vaccine 4 5 Razi Cov ParsVaccine descriptionTargetSARS CoV 2Vaccine typeProtein subunitClinical dataRoutes ofadministrationIntramuscular IntranasalLegal statusLegal statusFull list of Razi Cov Pars authorizations Contents 1 Medical uses 2 Pharmacology 3 Manufacturing 4 History 4 1 Clinical trials 5 See also 6 ReferencesMedical uses editIt requires three doses given day 0 intramuscular day 21 intramuscular and day 51 intranasal spray 3 Pharmacology editRazi Cov Pars is a recombinant protein subunit vaccine containing the SARS CoV 2 spike protein 2 Manufacturing editIt s planned to produce one million doses of the vaccine each month as of September 2021 4 As of 25 November 2021 5 millions doses have been delivered to the Iranian Ministry of Health 6 History editClinical trials edit Clinical trials of Razi Cov Pars Phase Registration number Start Number of participants Age of participants RefTotal Vaccine PlaceboI IRCT20201214049709N1 21 January 2021 133 30 5 µg 200µL 30 10 µg 200µL 30 20 µg 200µL 30 placebo 13 sentinel 18 50 years 2 II IRCT20201214049709N2 13 April 2021 500 18 70 years 3 III IRCT20201214049709N3 29 August 2021 41 128 20 564 0 placebo 20 564 Sinopharm BIBP vaccine 18 years 5 See also editPharmaceuticals in Iran COVID 19 pandemic in Iran COVID 19 vaccine clinical researchReferences edit a b Banihashemi SR Es Haghi A Fallah Mehrabadi MH Nofeli M Mokarram AR Ranjbar A et al 2022 Safety and Efficacy of Combined Intramuscular Intranasal RAZI COV PARS Vaccine Candidate Against SARS CoV 2 A Preclinical Study in Several Animal Models Frontiers in Immunology 13 836745 doi 10 3389 fimmu 2022 836745 PMC 9179012 PMID 35693788 a b c Phase I Safety and Immunogenicity of Razi SARS CoV 2 recombinant Spike protein vaccine Razi Cov Pars in healthy adults aged 18 55 years parallel 4 arms design adjuvant only and three vaccine doses of 5 10 and 20 µg 200µl a Randomised double blind clinical trial irct ir Iranian Registry of Clinical Trials Retrieved 21 March 2021 a b c Phase II Safety and Immunogenicity of RAZI SARS CoV 2 recombinant Spike protein vaccine RAZI Cov Pars in adults aged 18 70 years a Randomised double blind parallel 2 arms clinical trial Iranian Registry of Clinical Trials Retrieved 22 April 2021 a b COVID 19 vaccine Razi Cov Pars starts third clinical trial phase Tehran Times 27 August 2021 Retrieved 30 August 2021 a b IRCT Comparison of the safety and efficacy of Razi SARS CoV 2 recombinant Spike protein Razi Cov Pars and Sinopharm vaccines in adults aged 18 and over a phase III randomised double blind non inferiority clinical trial en irct ir Retrieved 30 August 2021 ۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد 5 million doses of Razi vaccine were delivered to the Ministry of Health ایسنا ISNA in Persian 25 November 2021 Retrieved 27 November 2021 nbsp Scholia has a profile for Razi Cov Pars Q106725976 Portals nbsp Medicine nbsp Viruses nbsp COVID 19 nbsp This article about COVID 19 vaccines is a stub You can help Wikipedia by expanding it vte nbsp This article about vaccines or vaccination is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Razi Cov Pars amp oldid 1181540088, wikipedia, wiki, book, books, library,
